Dow Today: Pfizer (PFE) Higher

The Dow Jones Industrial Average ( ^DJI) is trading up 31 points (+0.2%) at 15,005 as of Tuesday, Jul 2, 2013, 12:35 p.m. ET. During this time, 213.1 million shares of the 30 Dow components have changed hands vs. an average daily trading volume of 622.2 million. The NYSE advances/declines ratio sits at 1,611 issues advancing vs. 1,325 declining with 103 unchanged.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

The Dow component leading the way higher looks to be Pfizer (NYSE: PFE), which is sporting an eight-cent gain (+0.3%) bringing the stock to $27.86. This single gain is lifting the Dow Jones Industrial Average by 0.61 points or roughly accounting for 2% of the Dow's overall gain. Volume for Pfizer currently sits at 27.7 million shares traded vs. an average daily trading volume of 60.8 million shares.

Pfizer has a market cap of $197.91 billion and is part of the health care sector and drugs industry. Shares are up 11.7% year to date as of Monday's close. The stock's dividend yield sits at 3.4%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. The company has a P/E ratio of 19.9, above the S&P 500 P/E ratio of 17.7.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Hawkish Fed Sends Nasdaq and S&P 500 Lower

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux

The 6 Medications Being Used to Tackle the Opioid Epidemic

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle